SRP3182
VEGF human
Animal-component free, recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), suitable for cell culture
Sinonimo/i:
Folliculostellate cell-derived growth factor, Glioma-derived endothelial cell mitogen, VPF, Vascular Endothelial Growth Factor-A
Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
About This Item
Codice UNSPSC:
12352202
NACRES:
NA.32
Prodotti consigliati
Origine biologica
human
Ricombinante
expressed in E. coli
Saggio
≥98% (HPLC)
≥98% (SDS-PAGE)
Stato
lyophilized
Potenza
1.0-8.0 ng/mL
PM
38.2 kDa
Confezionamento
pkg of 10 μg
tecniche
cell culture | mammalian: suitable
Impurezze
<0.1 EU/μg endotoxin, tested
Colore
white
N° accesso UniProt
Condizioni di spedizione
wet ice
Temperatura di conservazione
−20°C
Informazioni sul gene
human ... VEGFA(7422)
Descrizione generale
VEGF (vascular endothelial growth factor) signals through the three receptors; fms-like tyrosine kinase (flt-1), KDR gene product (the murine homolog of KDR is the flk-1 gene product) and the flt4 gene product. Recombinant human VEGF is a 38.2kDa disulfide-linked homodimeric protein consisting of two 165 amino acid polypeptide chains.
Applicazioni
VEGF human has been used as a chemoattractant for HUVECs (human umbilical vein endothelial cells) migration assay.
Azioni biochim/fisiol
VEGF (vascular endothelial growth factor) is a potent growth and angiogenic cytokine. It stimulates proliferation and survival of endothelial cells, and promotes angiogenesis and vascular permeability. Expressed in vascularized tissues, VEGF plays a prominent role in normal and pathological angiogenesis. Substantial evidence implicates VEGF in the induction of tumor metastasis and intraocular neovascular syndromes. Polymorphism in VEGF at C(-634)G is linked with diabetic retinopathy in type 2 diabetes.
Sequenza
APMAEGGGQN HHEVVKFMDV YQRSYCHPIE TLVDIFQEYP DEIEYIFKPS CVPLMRCGGC CNDEGLECVP TEESNITMQI MRIKPHQGQH IGEMSFLQHN KCECRPKKDR ARQENPCGPC SERRKHLFVQ DPQTCKCSCK NTDSRCKARQ LELNERTCRC DKPRR
Stato fisico
Lyophilized with no additives.
Ricostituzione
Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a stabilizer (example 5% Trehalose) and store in working aliquots at -20°C to -80°C.
Codice della classe di stoccaggio
11 - Combustible Solids
Classe di pericolosità dell'acqua (WGK)
WGK 3
Punto d’infiammabilità (°F)
Not applicable
Punto d’infiammabilità (°C)
Not applicable
Scegli una delle versioni più recenti:
Certificati d'analisi (COA)
Lot/Batch Number
Non trovi la versione di tuo interesse?
Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.
Possiedi già questo prodotto?
I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.
I clienti hanno visto anche
Naoki Horikawa et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 23(2), 587-599 (2016-07-13)
High VEGF expression in ovarian cancer is an unfavorable prognostic factor. However, the role of VEGF in tumor immunity remains unclear. Here, we examined the impact of VEGF on local immunity, including induction of myeloid-derived suppressor cells (MDSC), in ovarian
Ca2+ influx through reverse mode Na+/Ca2+ exchange is critical for vascular endothelial growth factor-mediated extracellular signal-regulated kinase (ERK) 1/2 activation and angiogenic functions of human endothelial cells.
Andrikopoulos P
The Journal of Biological Chemistry, 286, 37919-37931 (2011)
Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa.
Andre T
International Journal of Cancer. Journal International Du Cancer, 86, 174-181 (2000)
VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis.
Hirakawa S
The Journal of Experimental Medicine, 20, 1089-1099 (2005)
M Clauss et al.
The Journal of experimental medicine, 172(6), 1535-1545 (1990-12-01)
Systemic infusion of low concentrations of tumor necrosis factor/cachectin (TNF) into mice that bear TNF-sensitive tumors leads to activation of coagulation, fibrin formation, and occlusive thrombosis exclusively within the tumor vascular bed. To identify mechanisms underlying the localization of this
Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..
Contatta l'Assistenza Tecnica.